Exiqon Array Sales, Services 'Stable' Despite Competition from Sequencing, qPCR | GenomeWeb

Exiqon continues to see demand for its microRNA microarray products, though its quantitative PCR assays and functional analysis products are driving its sales, according to its CEO Lars Kongsbak.

Exiqon has offered a line of its microRNA array tools and services since it first launched the chips in 2005. Last year, it introduced the seventh generation of its chips for expression profiling of microRNA from human, mouse, and rat (BAN 4/17/2012).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.